Objective:

To highlight the achievements and best practices of the USC Norris Blood and Marrow Transplant and Cell Therapy Program in achieving high survival outcomes in allogeneic transplants, including specific innovative techniques and comprehensive care strategies.

Key Findings:

• USC Norris Blood and Marrow Transplant and Cell Therapy Program achieved an 86% one-year survival rate, significantly higher than the national average.
• Only eight programs nationwide received a +1 score in the 2025 CIBMTR analysis.
• The program has maintained elite status for six consecutive years.

Interpretation:

The sustained high survival rates reflect the program's commitment to innovative practices, comprehensive care, and a collaborative team approach that addresses the multifaceted needs of patients.

Limitations:

• The article does not provide specific data on patient demographics or the types of conditions treated.
• Potential biases in self-reported outcomes and program evaluations.
• Lack of longitudinal data on patient outcomes post-transplant.

Conclusion:

The USC Norris Blood and Marrow Transplant and Cell Therapy Program exemplifies excellence in patient care through innovative practices and a multidisciplinary approach.